Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

DIAZEPAM 2 MG TABLET

DIAZEPAM
$0.0217per EA
DEA Schedule CIV

Strength

2 mg/1

Manufacturer

Aurobindo Pharma Limited

NDC

59651065205

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

DIAZEPAM

Approval Type

Generic (ANDA)

FDA Application

ANDA217843

On Market Since

12/14/2023

Pharmacological Classes

Benzodiazepine
Benzodiazepines

Price History

1W

0.0%

1M

+2.9%

3M

-1.5%

6M

-3.1%

1Y

-1.7%

3Y

N/A

5Y

N/A

All

-1.6%

Generic Alternatives

1 alternative • Same active ingredient

DIAZEPAM 2 MG TABLET
Generic
59651065201•Aurobindo Pharma Limited
$0.0217

Related Drugs

Same classification

CLONAZEPAM 0.5 MG TABLET
Generic
00093083201•Teva Pharmaceuticals USA Inc.
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
00093083205•Teva Pharmaceuticals USA Inc.
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
00904722761•Major Pharmaceuticals
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
16729013600•Accord Healthcare Inc.
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
16729013616•Accord Healthcare Inc.
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
43547040610•Solco Healthcare US LLC
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
43547040611•Solco Healthcare US LLC
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
43547040650•Solco Healthcare US LLC
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
50268017315•AvPAK
$0.0200
per EA
CLONAZEPAM 0.5 MG TABLET
Generic
59651072201•Aurobindo Pharma Limited
$0.0200
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy